Advertisement

Topics

Altus Biologics Incorporated Company Profile

04:26 EST 22nd November 2017 | BioPortfolio

Altus is a leading life sciences company, which has developed a unique, powerful and proprietary platform technology, known as Crystalomics™, to enable the rapid commercialization of high-value protein-based products. Our primary focus is on the $300 billion pharmaceutical industry, where the technology is designed to significantly accelerate the development of both large and small molecule pharmaceuticals.

Location

525 Putman venue
Cambridge
MA
02139-4807
United States of America

Contact

Phone: 617 299 2900
Fax: 617 299 2999
Email: info@altus.com


News Articles [453 Associated News Articles listed on BioPortfolio]

Majority of North American Medical School Applicants to Be Assessed With Innovative Tool From Canadian Tech Company, Altus Assessments

Enthusiastic response from academic programs represents a growing trend towards using reliable tools to measure non-academic traits of applicants. Toronto, Ontario (PRWEB) June 26, 2017 Altus Assessm...

Medical News Today: What are biologics for RA?

Biologics work by targeting the specific immune system cells that cause rheumatoid arthritis. Learn more about biologics in this article.

DSM Biologics: Karen King on New Technology and Reducing the Cost of Medicines

In this episode of PharmaTelevision News Review, Fintan Walton talks with Karen King, President and Business Unit Director of DSM Biologics. Filmed at BioChicago 2010 in Chicago, USA, they discuss: ...

Publication of the Securities Note Having Obtained Visa No. 17-297 of the AMF in Connection with the Capital Increase of GenSight Biologics

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN. Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), ("GenSight Biologics...

Heat Biologics, Inc.: Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics

DURHAM, NC / ACCESSWIRE / July 3, 2017 / Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...

Samsung Bioepis Forms Novel Biologics JV with Takeda Pharma

Samsung Bioepis, a division of Samsung Biologics, announced a joint venture with Japan's Takeda Pharma to develop novel biologic drugs. The JV's first project will be TAK-671, a candidate aimed at sev...

Heat Biologics, Inc.: Heat Biologics Appoints Damien Hallet as Vice President of CMC Development

DURHAM, NC / ACCESSWIRE / July 3, 2017 / Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...

Vical Incorporated Announces Pricing of $25 Million Underwritten Public Offering of Common Stock

SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the pricing of its underwritten public offering of 14,285,714 shares of common stock or common stock ...

PubMed Articles [102 Associated PubMed Articles listed on BioPortfolio]

Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.

Biologic disease-modifying anti-rheumatic drugs (DMARDs: referred to as biologics) are effective in treating rheumatoid arthritis (RA), however there are few head-to-head comparison studies. Our syste...

Prolongation of biologic dosing intervals in patients with stable psoriasis: a feasibility study.

Biologics are usually licensed according to the "one dose fits all" principle. It is therefore suspected that a significant number of psoriasis patients are overtreated. However, evidence for successf...

Biosimilars: biologics that meet patients' needs and healthcare economics.

Biologics have revolutionized medical care, yet uniform access to these effective medicines remains difficult due to the increasing costs of healthcare. As patent exclusivity on the early biologics wa...

The expanding field of biologics in the management of chronic urticaria.

Chronic urticaria (CU) is the occurrence of urticaria with or without angioedema for at least 6 weeks. Management has traditionally involved antihistamines as first-line therapy with various alternati...

Biologics for idiopathic inflammatory myopathies.

As treatment of refractory cases of idiopathic inflammatory myopathies (IIMs) has been challenging, there is growing interest in assessing novel biologics that target various pathways implicated in th...

Clinical Trials [62 Associated Clinical Trials listed on BioPortfolio]

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...

Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity

Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with sta...

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.

Companies [276 Associated Companies listed on BioPortfolio]

Altus Biologics

Altus is a leading life sciences company, which has developed a unique, powerful and proprietary platform technology, known as Crystalomics™, to enable the rapid commercialization of high-value prot...

Altus Biologics Incorporated

Altus is a leading life sciences company, which has developed a unique, powerful and proprietary platform technology, known as Crystalomics™, to enable the rapid commercialization of high-value prot...

Altus Pharmaceuticals Inc.

Altus® Pharmaceuticals is focused on developing and commercializing novel protein therapeutics for patients with chronic gastrointestinal and metabolic diseases. Altus' in-depth knowledge of protein ...

Burst Biologics

Burst Biologics is a rapidly growing Biotechnology Company and federally registered tissue bank located in Boise, Idaho. Burst Biologics is a developer of effective tissue process...

MSD Biologics (UK) Limited

Avecia Biologics was acquired in February 2010 by MSD, the UK subsidiary of Merck & Co Inc, the world’s second largest pharmaceutical company. MSD Billingham is one of the world's leading contract ...

More Information about "Altus Biologics Incorporated" on BioPortfolio

We have published hundreds of Altus Biologics Incorporated news stories on BioPortfolio along with dozens of Altus Biologics Incorporated Clinical Trials and PubMed Articles about Altus Biologics Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Altus Biologics Incorporated Companies in our database. You can also find out about relevant Altus Biologics Incorporated Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record